Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 02, 2018 16:05 ET | Source: TESARO, Inc.

TESARO Announces Second-Quarter 2018 Operating Results

ZEJULA® Q2 net sales totaled $54 million compared to $26 million for Q2 2017QUADRA sNDA submission planned for Q4 2018PRIMA Phase 3 ZEJULA monotherapy trial in first-line ovarian cancer regardless of...
July 20, 2018 16:15 ET | Source: TESARO, Inc.

TESARO to Announce Second-Quarter 2018 Financial Results on August 2, 2018

WALTHAM, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce second-quarter 2018 financial results on Thursday, August 2, 2018, after the close of the U.S. financial...
July 02, 2018 09:00 ET | Source: TESARO, Inc.

TESARO Partners With the Pan-Mass Challenge for 2018 Ride Benefiting Dana-Farber Cancer Institute

WALTHAM, Mass., July 02, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to announce a new partnership supporting the Pan-Mass Challenge...
June 29, 2018 16:05 ET | Source: TESARO, Inc.

TESARO Draws $200 Million From Second Tranche of Non-Dilutive Term Loan Financing

WALTHAM, Mass., June 29, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology focused biopharmaceutical company, announced today that it has drawn the $200 million second tranche under...
June 28, 2018 16:05 ET | Source: TESARO, Inc.

TESARO Enters Asset Purchase Agreement with TerSera® Therapeutics LLC for VARUBI® in the U.S. and Canada

TESARO to Receive $40 Million, plus Potential for Additional Milestone Payments and Royalties TESARO Retains ex-North America Rights and Continues to Market VARUBY® in Europe WALTHAM, Mass., June ...
June 05, 2018 08:30 ET | Source: TESARO, Inc.

TESARO Announces Collaboration to Evaluate ZEJULA® in Combination With Anti-PD-L1 Cancer Immunotherapy and MEK Inhibitor in Platinum-Sensitive Ovarian Cancer

WALTHAM, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into a clinical collaboration with...
June 04, 2018 18:00 ET | Source: TESARO, Inc.

TESARO Summarizes TOPACIO and QUADRA Trial Results Presented at 2018 ASCO Annual Meeting

TOPACIO data for ZEJULA® (niraparib) in combination with an anti-PD-1 mAb highlight promising activity in platinum-resistant/refractory ovarian cancer and triple-negative breast cancer beyond patients...
June 01, 2018 03:00 ET | Source: TESARO, Inc.

TESARO Announces Addition of ZEJULA to Cancer Drugs Fund in UK

Inclusion in the Cancer Drugs Fund will give more women in England and Wales with recurrent, platinum-sensitive ovarian cancer access to ZEJULA via a managed access arrangementZEJULA was launched in...
May 16, 2018 17:15 ET | Source: TESARO, Inc.

TESARO Announces Presentations of Abstracts at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Investor briefing to be webcast from Chicago on Monday, June 4, 2018 at 6:15PM CT WALTHAM, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical...
May 08, 2018 09:19 ET | Source: TESARO, Inc.

Psychological Effects of Ovarian Cancer Often Overlooked and Can Have a Significant Impact on Patients

79% of patients felt uncomfortable raising psychological and emotional concerns during their consultations1Disease recurrence is of greatest concern for ovarian cancer patients, but poorly addressed,...